Suchergebnisse

Public concern for the conservation of natural resources and a general awareness of the environmental consequences of waste disposal is reflected in current legislation aimed at reducing waste. Recycling is commonly cited as one of the preferred methods of waste reduction and this book summarizes a recent study of paper recycling in Europe, which investigated the entire production and disposal process using a life-cycle methodology. The results of the study underline the economic and environmental advantages of paper recycling, but more controversially, they also show how, under certain condit.

'The authors take us into less-known corridors of climate Realpolitik and energy power play. We are provided with the essential vocabulary to understand what is at stake and how the challenge should be tackled' Prince Sadruddin Aga Khan Global warming and the resulting climate change present one of the greatest potential threats humanity has had to face. Every country contributes to them and they affect every person. Correspondingly, the Framework Convention on Climate Change, negotiated at the Earth Summit and since, is potentially one of the most significant international agreements ever reached � and its successful implementation is vital if the threat is to be averted. This book provides a guide to the Convention and explains in very clear terms what is involved: the background which makes it so necessary; the tortuous process involved in negotiating it; what it says; and most importantly, how it must be interpreted and implemented, making clear the scale of the changes involved and the dangers of evading them. Sten Nilsson is leader of the forest resources project at the International Institute for Applied Systems Analysis. David Pitt is a consultant to the Bellerive Foundation and Alp Action. They are the authors of Mountain World in Danger, published by Earthscan in 1991. Originally published in 1994.

Benefits of dealing with uncertainty in greenhouse gas inventories: introduction -- Statistical dependence in input data of national greenhouse gas inventories: effects on the overall inventory uncertainty -- Uncertainty analysis for estimation of landfill emissions and data sensitivity for the input variation -- Toward Bayesian uncertainty quantification for forestry models used in the United Kingdom Greenhouse Gas Inventory for land use, land use change, and forestry -- Atmospheric inversions for estimating CO2 fluxes: methods and perspectives -- European CO2 fluxes from atmospheric inversions using regional and global transport models -- Remotely sensed soil moisture integration in an ecosystem carbon flux model. The spatial implication -- Can the uncertainty of full carbon accounting of forest ecosystems be made acceptable to policymakers? -- Terrestrial full carbon account for Russia: revised uncertainty estimates and their role in a bottom-up/top-down accounting exercise -- Comparison of preparatory signal analysis techniques for consideration in the (post- )Kyoto policy process -- Verification of compliance with GHG emission targets: annex B countries -- Spatial GHG inventory at the regional level: accounting for uncertainty -- Quantitative quality assessment of the greenhouse gas inventory for agriculture in Europe -- A statistical model for spatial inventory data: a case study of N2O emissions in municipalities of southern Norway -- Carbon emission trading and carbon taxes under uncertainties -- CO2 emission trading model with trading prices -- Compliance and emission trading rules for asymmetric emission uncertainty estimates -- The impact of uncertain emission trading markets on interactive resource planning processes and international emission trading experiments

This book offers approaches for assessing and managing greenhouse gas inventories, including the benefits of incorporating uncertainty in policy analyses. Comprehensive treatment of uncertainty can help reduce errors, and lead to more sophisticated solutions.

Addresses key uncertainty issues - verification, compliance and emissions tradingPresents state-of-the-art research and developments Provides a multidisciplinary forum for international experts Can be used in various courses in environmental management and environmental economics.

Public concern for the conservation of natural resources and a general awareness of the environmental consequences of waste disposal is reflected in current legislation aimed at reducing waste. Recycling is commonly cited as one of the preferred methods of waste reduction and this book summarizes a recent study of paper recycling in Europe, which investigated the entire production and disposal process using a life-cycle methodology. The results of the study underline the economic and environmental advantages of paper recycling, but more controversially, they also show how, under certain conditions, the renewable character and the high energy content of paper seem to make energy recovery more attractive than recycling.

17 pages ; 21 cm ; Bibliography p. 14-17 ; The paper addresses the problem of uncertainty in the national inventories of greenhouse gas emissions and removals, published annually by parties to the United Nations Framework Convention on Climate Change, and used by policymakers to develop strategies and policies for emission reductions and to track the progress of these policies. The importance of scientific, economic, and political implications of uncertainty is stresssed and an overview of the state of the art of analyzing emission changes in consideration of uncertainty is provided. ; 17 stron ; 21 cm ; Bibliografia s. 14-17 ; The paper addresses the problem of uncertainty in the national inventories of greenhouse gas emissions and removals, published annually by parties to the United Nations Framework Convention on Climate Change, and used by policymakers to develop strategies and policies for emission reductions and to track the progress of these policies. The importance of scientific, economic, and political implications of uncertainty is stresssed and an overview of the state of the art of analyzing emission changes in consideration of uncertainty is provided.

BackgroundRadium-223, a targeted alpha therapy, is used to treat symptomatic patients with castration-resistant prostate cancer (CRPC) and bone metastases. Data for radium-223 in asymptomatic CRPC patients with bone metastases are lacking.MethodsThis was a prospective, single-arm phase 3b study. Patients with metastatic CRPC (malignant lymphadenopathy not exceeding 6cm was allowed, visceral disease was excluded) received radium-223, 55kBq/kg intravenously, every 4weeks for up to 6cycles. Co-primary endpoints were safety and overall survival. Post hoc analyses were performed according to baseline asymptomatic or symptomatic disease status. Asymptomatic status was defined as no pain and no opioid use at baseline.ResultsSeven hundred eight patients received 1 radium-223 injection: 548 (77%) were symptomatic to various degrees, and 135 (19%) were asymptomatic. Asymptomatic patients had more favorable baseline disease characteristics than symptomatic. A lower proportion of asymptomatic versus symptomatic patients had received prior abiraterone (25% vs 35%) and prior docetaxel (52% vs 62%). A higher proportion of asymptomatic (71%) versus symptomatic (55%) patients completed radium-223 treatment. Overall survival (hazard ratio [HR] 0.486), time to disease progression (HR 0.722) and time to first symptomatic skeletal event (HR 0.328) were better in asymptomatic than symptomatic patients. Alkaline phosphatase (ALP) response rates were similar (46% vs 47%), and ALP normalization (44% vs 25%) and prostate-specific antigen response rates (21% vs 13%) were higher in asymptomatic than symptomatic patients. A lower proportion of asymptomatic patients reported treatment-emergent adverse events (TEAEs, 61% vs 79%), grade 3-4 TEAEs (29% vs 40%) and drug-related TEAEs (28% vs 44%). There were two treatment-related deaths, both in patients with baseline symptomatic disease.ConclusionsUsing radium-223 earlier in the disease course, when patients are asymptomatic or minimally symptomatic, may enable patients to complete treatment and optimize treatment outcome compared to symptomatic patients, and therefore may allow sequencing with other life-prolonging therapies.Trial registrationThe study was registered with ClinicalTrials.gov, number NCT01618370 on June 13, 2012 and the European Union Clinical Trials Register, EudraCT number 2012-000075-16 on April 4, 2012.

Background In the previously reported ALSYMPCA trial in patients with castration-resistant prostate cancer and symptomatic bone metastases, overall survival was significantly longer in patients treated with radium-223 dichloride (radium-223) than in patients treated with placebo. In this study, we investigated safety and overall survival in radium-223 treated patients in an early access programme done after the ALSYMPCA study and before regulatory approval of radium-223. Methods We did an international, prospective, interventional, open-label, single-arm, phase 3b study. Enrolled patients were aged 18 years or older with histologically or cytologically confirmed progressive bone-predominant metastatic castration-resistant prostate cancer with two or more skeletal metastases on imaging (with no restriction as to whether they were symptomatic or asymptomatic; without visceral disease but lymph node metastases were allowed). Patients received intravenous injections of radium-223, 50 kBq/kg (current recommendation 55 kBq/kg after implementation of National Institute of Standards and Technology update on April 18, 2016) every 4 weeks for up to six injections. Other concomitant anticancer therapies were allowed. Primary endpoints were safety and overall survival. The safety and efficacy analyses were done on all patients who received at least one dose of the study drug. The study has been completed, and we report the final analysis here. This study is registered with ClinicalTrials.gov, number NCT01618370, and the European Union Clinical Trials Register, EudraCT number 2012-000075-16. Findings Between July 22, 2012, and Dec 19, 2013, 839 patients were enrolled from 113 sites in 14 countries. 696 patients received one or more doses of radium-223; 403 (58%) of these patients had all six planned injections. Any-grade treatment-emergent adverse events occurred in 523 (75%) of 696 patients; any-grade treatment-emergent adverse events deemed to be related to treatment were reported in 281 (40%) patients. The most common grade 3 or worse treatment-related treatment-emergent adverse events were anaemia in 32 (5%) patients, thrombocytopenia in 15 (2%) patients, neutropenia in ten (1%) patients, and leucopenia in nine (1%) patients. Any grade of serious adverse events were reported in 243 (35%) patients. Median follow-up was 7 . 5 months (IQR 5-11) and 210 deaths were reported; median overall survival was 16 months (95% CI 13-not available [NA]). In an exploratory analysis of overall survival with predefined factors, median overall survival was longer for: patients with baseline alkaline phosphatase concentration less than the upper limit of normal (ULN; median NA, 95% CI 16 months-NA) than for patients with an alkaline phosphatase concentration equal to or greater than the ULN (median 12 months, 11-15); patients with baseline haemoglobin levels 10 g/dL or greater (median 17 months, 14-NA) than for patients with haemoglobin levels less than 10 g/dL (median 10 months, 8-14); patients with a baseline Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 (median NA, 17 months-NA) than for patients with an ECOG PS of 1 (median 13 months, 11-NA) or an ECOG PS of 2 or more (median 7 months, 5-11); and for patients with no reported baseline pain (median NA, 16 months-NA) than for those with mild pain (median 14 months, 13-NA) or moderate-severe pain (median 11 months, 9-13). Median overall survival was also longer in patients who received radium-223 plus abiraterone, enzalutamide, or both (median NA, 95% CI 16 months-NA) than in those who did not receive these agents (median 13 months, 12-16), and in patients who received radium-223 plus denosumab (median NA, 15 months-NA) than in patients who received radium-223 without denosumab (median 13 months, 12-NA). Interpretation Our findings show that radium-223 can be safely combined with abiraterone or enzalutamide, which are now both part of the standard of care for patients with metastatic castration-resistant prostate cancer. Furthermore, our findings extend to patients who were asymptomatic at baseline, unlike those enrolled in the pivotal ALSYMPCA study. The findings of prolonged survival in patients treated with concomitant abiraterone, enzalutamide, or denosumab require confirmation in prospective randomised trials.